[go: up one dir, main page]

WO2021167098A1 - Indice d'évaluation quantitative pour restriction de croissance foetale - Google Patents

Indice d'évaluation quantitative pour restriction de croissance foetale Download PDF

Info

Publication number
WO2021167098A1
WO2021167098A1 PCT/JP2021/006475 JP2021006475W WO2021167098A1 WO 2021167098 A1 WO2021167098 A1 WO 2021167098A1 JP 2021006475 W JP2021006475 W JP 2021006475W WO 2021167098 A1 WO2021167098 A1 WO 2021167098A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
group
body fluid
cells
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2021/006475
Other languages
English (en)
Japanese (ja)
Inventor
義朗 佐藤
忍 清水
昌弘 早川
悠磨 北瀬
淳人 小野田
雅弘 辻
真理 出澤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tokai National Higher Education and Research System NUC
Original Assignee
Tokai National Higher Education and Research System NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokai National Higher Education and Research System NUC filed Critical Tokai National Higher Education and Research System NUC
Priority to JP2022501095A priority Critical patent/JPWO2021167098A1/ja
Publication of WO2021167098A1 publication Critical patent/WO2021167098A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N37/00—Details not covered by any other group of this subclass

Definitions

  • the present invention provides a biomarker for early determination, diagnosis, or assistance in diagnosis of perinatal disorder in a newborn due to fetal stunting, and early determination or early determination of perinatal disorder in a newborn using the biomarker.
  • the present invention relates to an early diagnosis method and a method for determining the therapeutic effect of perinatal disorders at an early stage using the biomarker.
  • Pregnancy is associated with increased maternal cardiac output and a vast increase in uterine perfusion resulting from trophoblast-driven modification of the uterine spiral artery. Failure of this normal physiological process is also known as two of the most difficult obstetric complications, Fetal Growth Restriction (FGR) (or Intrauterine Growth Restriction; IUGR). Is involved in the causes of pre-eclampsia (pre-eclampsia) and pre-eclampsia (PET).
  • FGR Fetal Growth Restriction
  • IUGR Intrauterine Growth Restriction
  • Fetal growth restriction affects up to 8% of all pregnancies and is associated with high perinatal mortality, long-term neurological disorders and an increased incidence of cardiovascular disease in later years, based on evidence. There is no effective treatment. Severe early-onset fetal growth restriction affects 1: 500 pregnancies and is associated with high mortality and long-term complications in survivors. In the most severe cases, a viable birth weight (at least 500 g) cannot be reached, forcing a strict choice between abortion or allowing the foetation to die in utero. Small improvements in fetal growth (eg, up to 700 g birth weight) and birth gestation (eg, 26-28 weeks) are associated with major improvements in survival and morbidity.
  • Patent Document 1 proposes a therapeutic strategy that has succeeded in early evaluation and diagnosis of perinatal brain disorders (for example, neurodevelopmental disorders) due to fetal growth restriction.
  • the present invention overcomes the above-mentioned problems and diagnoses perinatal brain disorders (for example, neurodevelopmental disorders) in newborns associated with fetal growth restriction with high sensitivity, appropriately and accurately, thereby causing neurodevelopmental disorders at an early stage. Furthermore, it is an object of the present invention to determine an optimal treatment policy and to provide an evaluation / diagnosis method for early evaluation of the effect of intervening treatment in a newborn baby. The present invention also provides information that is the basis for elucidating the pathophysiology of perinatal brain disorders associated with fetal growth restriction.
  • the present inventors comprehensively analyzed proteins in cerebrospinal fluid from a rat model of fetal growth restriction, and as a result, evaluated, diagnosed, predicted, and treated developmental disorders associated with fetal growth restriction.
  • a method for early determination of perinatal disorders in newborns due to fetal growth restriction in mammalian subjects (A) ⁇ -2-Macroglobulin (A2m) (SEQ ID NO: 1), OX-2 membrane glycoprotein (Cd200) (SEQ ID NO: 2), polyubiquitin-B (Ubb) (SEQ ID NO: 3), neurocerpin (Serpini1) ) (SEQ ID NO: 4), ubiquitin thioesterase OTUB1 (Otub1) (SEQ ID NO: 5), and one or more proteins selected from the group consisting of ubiquitin-like modification activating enzyme 1 (Uba1) (SEQ ID NO: 6).
  • Expression levels were tested in body fluid samples obtained from subjects in comparison to expression levels in normal body fluids, post-treatment body fluids, or body fluids known to exhibit perinatal disorders; and (b).
  • the expression level is statistically significantly different from the expression level in the normal body fluid or the body fluid after treatment, or is compared with the expression level in the body fluid known to exhibit perinatal disorders.
  • the above method which comprises evaluating the subject as having a perinatal disorder when it does not show a statistically significant difference.
  • the protein is selected from the group consisting of ⁇ -2-macroglobulin (A2m), OX-2 membrane glycoprotein (Cd200), polyubiquitin-B (Ubb), and neuroserpin (Serpini1). 1] The method described in.
  • [3] The method according to [1] or [2], wherein the subject is a human patient.
  • [4] When all of the tested proteins show a significant difference in the body fluid sample of the subject as compared with the normal body fluid, the subject is evaluated as having a perinatal disorder, [1] to The method according to any one of [3].
  • [5] The method according to any one of [1] to [4], wherein the expression level is determined by an immunoassay.
  • [6] The method according to any one of [1] to [4], wherein the expression level is determined by liquid chromatography / mass spectrometry.
  • [7] The method according to any one of [1] to [4], wherein the expression level is determined using a protein array.
  • -2 Selected from the group consisting of membrane glycoprotein (Cd200), polyubiquitin-B (Ubb), neuroserpin (Serpini1), ubiquitin thioesterase OTUB1 (Otub1), and ubiquitin-like modification activating enzyme 1 (Uba1) 1
  • -2 selected from the group consisting of membrane glycoprotein (Cd200), polyubiquitin-B (Ubb), neuroserpin (Serpini1), ubiquitin thioesterase OTUB1 (Otub1), and ubiquitin-like modification activating enzyme 1 (Uba1) 1
  • Uba1 ubiquitin-like modification activating enzyme 1
  • the protein is selected from the group consisting of ⁇ -2-macroglobulin (A2m), OX-2 membrane glycoprotein (Cd200), polyubiquitin-B (Ubb), and neuroserpin (Serpini1). 8] Use described in. [10] A method for early determination of the therapeutic effect of neonatal perinatal disorders caused by fetal growth restriction in a mammalian subject.
  • A ⁇ -2-Macroglobulin (A2m) (SEQ ID NO: 1), OX-2 membrane glycoprotein (Cd200) (SEQ ID NO: 2), polyubiquitin-B (Ubb) (SEQ ID NO: 3), neurocerpin (Serpini1) ) (SEQ ID NO: 4), ubiquitin thioesterase OTUB1 (Otub1) (SEQ ID NO: 5), and one or more proteins selected from the group consisting of ubiquitin-like modification activating enzyme 1 (Uba1) (SEQ ID NO: 6).
  • Expression levels were tested in body fluid samples obtained from the subject being treated in comparison to expression levels in normal body fluids, post-treatment body fluids, or body fluids known to exhibit perinatal disorders; (B) In the body fluid known to show no statistically significant difference in expression level compared to the expression level in the normal body fluid or body fluid after treatment, or to exhibit perinatal disorders.
  • the above method comprising determining that treatment of perinatal disorders in the subject is effective when it shows a statistically significant difference compared to the expression level.
  • the protein is selected from the group consisting of ⁇ -2-macroglobulin (A2m), OX-2 membrane glycoprotein (Cd200), polyubiquitin-B (Ubb), and neuroserpin (Serpini1). 10].
  • the biomarker of the present invention by using the biomarker of the present invention, the onset of perinatal brain disorder can be predicted in the neonatal period, and the onset of neurodevelopmental disorder in infants or children can be predicted at an early stage. Therefore, it is possible to perform optimal diagnostic guidelines, treatment evaluation, and elucidation of pathological conditions in newborn babies.
  • ⁇ -2-Macroglobulin was identified by proteomics analysis as a protein with significant variation.
  • Neuroserpin (Serpini1) has been identified by proteomics analysis as a protein with significant variation.
  • Polyubiquitin-B (Ubb) was identified by proteomics analysis as a protein with significant variation.
  • the OX-2 membrane glycoprotein (Cd200) was identified by proteomics analysis as a protein showing significant variation.
  • Ubiquitin thioesterase OTUB1 (Otub1) has been identified by proteomics analysis as a protein with significant variation.
  • Ubiquitin-like modification activating enzyme 1 (Uba1 or Ube1) was identified by proteomics analysis as a protein showing significant variation.
  • A2m over time in the fetal growth restriction model (“FGR”) and the sham surgery group (“Sham”) is shown.
  • A2m expression in cerebrospinal fluid over time in various fetal growth restriction model groups sham surgery group (“Sham”), vehicle group (Vehicle)), MSC group (“MSC”), and Muse group (“Muse”)
  • the result of the measurement is shown.
  • A2m expression in serum in various fetal growth restriction model groups sham surgery group (“Sham”), vehicle group (Vehicle)), MSC group (“MSC”), and Muse group (“Muse” over time The measurement result is shown.
  • Serpini1 over time in the fetal growth restriction model (“FGR”) and the sham surgery group (“Sham”) is shown.
  • Serpini1 expression in cerebrospinal fluid over time in various fetal growth restriction model groups sham surgery group (“Sham”), vehicle group (Vehicle)), MSC group (“MSC”), and Muse group (“Muse”)
  • the result of the measurement is shown.
  • Serum expression in serum in various fetal growth restriction model groups sham surgery group (“Sham”), vehicle group (Vehicle)), MSC group (“MSC”), and Muse group (“Muse” over time The measurement result is shown.
  • Ubb expression in cerebrospinal fluid over time in various fetal growth restriction model groups (sham surgery group (“Sham”), vehicle group (Vehicle)), MSC group (“MSC”), and Muse group (“Muse”))
  • Sham fetal growth restriction model
  • MSC MSC group
  • Muse Muse group
  • Serum Ubb expression in various fetal growth restriction model groups (sham surgery group (“Sham”), vehicle group (Vehicle)), MSC group (“MSC”), and Muse group (“Muse”) over time The measurement result is shown.
  • Cd200 over time in the fetal growth restriction model (“FGR”) and the sham surgery group (“Sham”) is shown.
  • FGR fetal growth restriction model
  • Sham sham surgery group
  • MSC MSC group
  • Muse Muse group
  • Serum Cd200 expression in various fetal growth restriction model groups sham surgery group (“Sham”), vehicle group (Vehicle)), MSC group (“MSC”), and Muse group (“Muse” over time The measurement result is shown.
  • Otub1 over time in the fetal growth restriction model (“FGR”) and the sham surgery group (“Sham”) is shown.
  • FGR fetal growth restriction model
  • Sham vehicle group
  • MSC MSC group
  • Muse Muse group
  • the expression intensities of various biomarkers corresponding to FIG. 13B are shown.
  • the expression intensities of various biomarkers corresponding to FIG. 13C are shown. Indicates the location of the striatum of the brain.
  • the results of observing the expression of various biomarkers by tissue staining in each cell constituting the striatum in the fetal growth restriction model (“FGR”) and the sham surgery group (“Sham”) are shown.
  • the results of observing the expression of various biomarkers by tissue staining in each cell constituting the striatum in the fetal growth restriction model (“FGR”) and the sham surgery group (“Sham”) are shown.
  • the expression intensities of various biomarkers corresponding to FIG. 14B are shown.
  • FIG. 14C Indicates the location of the cerebral cortex of the brain.
  • the results of observing the expression of various biomarkers by tissue staining in each cell constituting the cerebral cortex in the fetal growth restriction model (“FGR”) and the sham surgery group (“Sham”) are shown.
  • the results of observing the expression of various biomarkers by tissue staining in each cell constituting the cerebral cortex in the fetal growth restriction model (“FGR”) and the sham surgery group (“Sham”) are shown.
  • the expression intensities of various biomarkers corresponding to FIG. 15B are shown.
  • the expression intensities of various biomarkers corresponding to FIG. 15C are shown.
  • the present invention provides a biomarker for early determination, diagnosis or assistance in diagnosis of perinatal brain disorder caused by fetal stunting, and early determination or early diagnosis of perinatal disorder in a newborn using the biomarker.
  • the present invention relates to a method and a method for determining the therapeutic effect of perinatal disorders at an early stage using the biomarker.
  • Fetal growth restriction is greatly involved in the life and neurological prognosis of the offspring. Fetal growth restriction is defined as a condition in which fetal growth is impaired in utero for some reason and the number of weeks of growth is impaired. At present, with the development of ultrasonic inspection equipment, it is common to make a diagnosis using ultrasonic inspection.
  • Fetal growth restriction is a heterogeneous disease, but fetal growth restriction that develops from the second trimester of pregnancy is often caused by congenital infections, genetic abnormalities, and congenital malformations, and intervention improves the prognosis of fetal growth restriction. It has been considered unlikely.
  • the fetal growth restriction that develops from the second trimester of pregnancy includes a group caused by placental dysfunction including the involvement of preeclampsia (HDP). Fetal growth restriction due to placental dysfunction has a worse prognosis when it develops in the second trimester of pregnancy than in the third trimester of pregnancy. It came to be divided. These are often separated by 32 to 34 weeks, although the definition varies from report to report.
  • TRUFFLE study a large-scale prospective observational study (TRUFFLE study) was reported in 2013. Between 2005 and 2010, 503 cases of early-onset fetal growth restriction who delivered between 26 and 32 weeks were registered at a facility centered on Europe. Fetal growth restriction was defined as a case in which the estimated fetal abdominal circumference was less than the 10th percentile and the umbilical artery blood flow pulsatile index was greater than or equal to the 95th percentile.
  • Fetal cell development is the period when the cell number itself increases rapidly in the first trimester of pregnancy (from the first trimester to the 16th week of pregnancy), and the cell itself as the number of cells increases in the second trimester of pregnancy (17th to 32nd week of pregnancy).
  • the period of hypertrophy, the third trimester of pregnancy (after 33 weeks of gestation), is the period in which the number of cells hardly increases and the cells become hypertrophied.
  • Fetal growth restriction is broadly classified into three types according to fetal cell development. The Consumer story is given in the next section, and the relationship between clinical classification and causes is shown in Table 1 below. However, there are many exceptions, and at present, it is rarely classified into type 1 and type 2.
  • Type 1 (symmetrical type) When the foetation is damaged in the early stages of pregnancy due to abnormalities of the foetation itself such as chromosomal abnormalities or TORCH syndrome, cell division and cell proliferation of the fetal organs are inhibited, so the size of the cells constituting the organs is normal. It exhibits hypoplasia with a small number of cells and is classified as type 1.
  • the hypoplastic type is characterized by well-proportioned growth in which the head and trunk are similarly suppressed because of the small number of foets, and the well-proportioned dysgenesis is called the symmetric type. Type 1 accounts for about 20% of all fetal growth restriction.
  • Type 2 (Asymmetric type) When a disorder occurs in the third trimester of pregnancy, cell division is already completed and cell hypertrophy is suppressed. When the number of cells is normal but the cells themselves are small, a malnutrition state called type 2 occurs. It is often caused by pathological abnormalities of the placenta caused by maternal diseases such as preeclampsia and diabetes that develop in late pregnancy. When fetal placenta circulation deteriorates, a vasodilatory effect (blood flow redistribution) occurs to protect important organs such as the brain, heart, and adrenal gland, and maintenance of cerebral blood flow is prioritized, so head growth is maintained.
  • a vasodilatory effect blood flow redistribution
  • Type 2 (asymmetric type) accounts for about 70% of all fetal growth restriction. However, it should be noted that when the brain sparring effect collapses and the growth of the head is impaired, it shifts to the symmetrical type (http://www.chugaiigaku.jp/upfile/browse/browse2521.pdf). Quoted from).
  • Perinatal encephalopathy refers to cerebral disorders that occur during the perinatal period (from 22 weeks gestation to less than 7 days after birth in humans), for example, low during labor. It means a brain disorder associated with oxygen-ischemic encephalopathy or systemic inflammatory reaction syndrome secondary to viral or bacterial infection.
  • the present invention also covers the time when neurodevelopmental disorders caused by fetal growth restriction are embodied as symptoms (for example, 2 to 3 years old in humans). More specifically, according to the present invention, perinatal brain disorders occur in human neonates (within 28 days of age), infants (less than 1 year of age), and infants (1 to 6 years of age). Target for improvement and treatment of brain disorders.
  • Cerebral palsy refers to irreversible cerebral palsy that occurs during the developmental period of the brain (in humans, it refers to the age of 13 days to 48 days after birth), and has non-progressive lesions, the symptoms of which are It is based on motor dysfunction, and most develop by the age of three. Specifically, it generally refers to brain damage that occurs by the neonatal period. The causes are divided according to the time of occurrence of the disorder.
  • Prenatal causes include intrauterine infection, placental insufficiency, fetal cerebrovascular accident, hereditary, etc.
  • birth causes include , Mechanical damage during labor, cerebral hemorrhage, anoxia, hypoxia, cerebral circulatory disorder, etc.
  • Postnatal causes include severe kernicterus (kernicterus), intracranial infection, cerebral hemorrhage, etc. Classification is based on the content of the paralysis.
  • the contents of muscle tone include strong (convulsive) straightness, toughness, ataxia, athetosis (involuntary movement that appears when maintaining a certain posture or trying to exercise), non-tension, etc.
  • Extremity paralysis hemiplegia, diplegia, paraplegia, double hemiplegia, monoplegia, etc.
  • Complications include intellectual disability (including learning disabilities), seizures, neurological disorders, and speech disorders.
  • Brain lesions caused by hypoxic-ischemic encephalopathy in mature infants are often cerebral cortical layer necrosis, basal ganglia necrosis, cerebral infarction, leukomalacia, bridge-shaped circumflex necrosis, and brain stem necrosis.
  • Basal ganglia necrosis causes atetose-type cerebral palsy
  • cerebral infarction causes spastic limb palsy and hemiplegia.
  • Brainstem necrosis often causes poor prognosis and death in infancy, and even if it survives, it causes dysphagia and respiratory dysregulation.
  • head ultrasound imaging, MRI, CT, electroencephalogram, and laser Doppler blood flow meters can be used to obtain physiological findings of the brain. Perinatal brain damage can be suspected if abnormal findings are obtained using these devices. In addition, it may be possible to make a diagnosis by directly observing learning disabilities and motor disorders in the subject.
  • perinatal brain disorders in newborns caused by fetal stunting in a mammalian subject can be detected.
  • a method for early determination, diagnosis or assistance (hereinafter, may be simply referred to as "early diagnosis method") is characterized in that one or more of six types of biomarkers described later are used.
  • the biomarkers (proteins) used are the expression level of proteins present in the body fluids of newborns who are thought to have the above-mentioned diseases, the expression levels of proteins present in normal body fluids or body fluids after treatment, or the diseases.
  • the expression level of the protein present in the body fluid of the subject is identified by comparing the expression level of the protein present in the body fluid of the subject known to show the presence or absence of the difference, or by identifying the protein that is upregulated or downregulated.
  • a biological sample eg, body fluid, tissue, organism, or cell culture
  • the expression level of the protein can be determined by using an immunoassay, mass spectrometry, or a protein array.
  • proteomics generally refers to (1) separation of individual proteins in a sample by two-dimensional gel electrophoresis; (2) identification of individual proteins recovered from the gel, such as liquid chromatography, mass spectrometry or N-terminal sequencing. Includes steps of singing and (3) analyzing data using bioinformatics. Proteomics methods can be a useful complement to other gene expression profiling methods.
  • the present invention mainly performs proteomic analysis of body fluids, but the "body fluids” used are not limited to cerebrospinal fluid (CSF), cord blood, cervical-vaginal fluid (CVF), amniotic fluid, and the like. Examples include blood, serum, plasma, urine, breast milk, mucus, saliva and sweat.
  • cerebrospinal fluid is preferable as the body fluid for diagnosing perinatal brain disorder associated with fetal growth restriction, which is a risk of neurodevelopmental disorder. This is because the information on biomolecules circulating in the brain due to the inflow and outflow of cerebrospinal fluid sensitively reflects the state of brain tissue and its changes.
  • serum which is the outflow destination of cerebrospinal fluid, is useful because it is non-invasive and can be easily collected.
  • Proteins present in biological samples are generally separated by two-dimensional gel electrophoresis according to pI and molecular weight. Proteins are first separated by their charge using isoelectric focusing (one-dimensional gel electrophoresis). This step may be performed using, for example, a commercially available fixed pH gradient (IPG) stripe.
  • IPG fixed pH gradient
  • the second dimension can be a conventional SDS-PAGE analysis, where concentrated IPG stripes are used as the sample.
  • proteins can be visualized by conventional dyes such as Coomassie blue or silver stain and can be imaged using known techniques and equipment such as Bio-Rad GS800 densitometer and PDQUEST software. can.
  • the individual spots are then excised from the gel, decolorized and trypsined.
  • the peptide mixture may be analyzed by mass spectrometry (MS).
  • MS mass spectrometry
  • HPLC capillary high performance liquid chromatography
  • the mass spectrometer consists of an ion source, a mass analyzer, an ion detector and a data acquisition unit.
  • the fragmented peptide is ionized at the ion source.
  • the ionized peptides are then separated by mass / charge ratio in a mass spectrometer to detect different ions.
  • mass spectrometry has been widely used in protein analysis since the development of matrix-assisted laser desorption / ionization / time-of-flight (MALDI-TOF) and electrospray ionization (ESI) methods.
  • MALDI-TOF and quadrupole-TOF, or an ion trap mass spectrometer connected to ESI are exemplified.
  • Protein arrays fix proteins on solid surfaces such as glass, silicon, microwells, nitrocellulose, PVDF membranes and microbeads using a variety of covalent and non-covalent attachment chemistries well known in the art. It is formed by doing.
  • the solid support is chemically stable before and after the coupling procedure, allows for good spot morphology, represents very small non-specific bonds, does not affect the background of the detection system, and does not affect the background of the detection system. Must be compatible with different detection systems.
  • the diagnostic method of the present invention may be carried out in the form of various immunoassay formats, which are well known in the art.
  • immunoassay formats There are two main types of immunoassays, homologous and heterogeneous.
  • an allogeneic immunoassay the immune response and detection between an antigen and an antibody is carried out in an allogeneic reaction.
  • the heterologous immunoassay comprises at least one separation step of separating the reaction product from the unreacted reagent.
  • the six proteins used in the present invention are proteins (or peptides) found in all 601 proteins based on the comprehensive analysis by the above proteomics. Specifically, ⁇ -2-macroglobulin (A2m) (SEQ ID NO: 1), OX-2 membrane glycoprotein (Cd200) (SEQ ID NO: 2), polyubiquitin-B (Ubb) (SEQ ID NO: 3), neurocerpin. (Serpini1) (SEQ ID NO: 4), ubiquitin thioesterase OTUB1 (Otub1) (SEQ ID NO: 5), and ubiquitin-like modification activating enzyme 1 (Uba1) (SEQ ID NO: 6). Information on the amino acid sequences of these proteins is available using publicly available databases (eg, UniProt; https://www.uniprot.org/).
  • At least one, preferably at least two, three, four or five, or all of the above proteins is used.
  • four of the above six proteins that is, ⁇ -2-macroglobulin (A2m), OX-2 membrane glycoprotein (Cd200), polyubiquitin-B (that is, polyubiquitin-B) Ubb) and neuroserpin (Serpini1)
  • A2m ⁇ -2-macroglobulin
  • Cd200 OX-2 membrane glycoprotein
  • polyubiquitin-B that is, polyubiquitin-B) Ubb
  • neuroserpin Serpini1
  • these proteins have been shown to improve their expression fluctuations from an early stage by administration of pluripotent stem cells (Muse cells).
  • At least three are also found in neonatal serum. It was confirmed that there was a significant change in expression associated with fetal growth restriction and improvement of the change was observed by administration of pluripotent stem cells (Muse cells).
  • Fluctuations in the expression levels of the above 6 or 4 proteins in body fluid samples are known to indicate normal body fluids, post-treatment body fluids (due to drugs, pluripotent stem cells, etc.), or perinatal disorders. It is done by comparing with the expression level in the body fluid.
  • the body fluid used as the comparison standard is a normal body fluid or a body fluid after treatment
  • the expression level of the fluctuation is 1.1 times, 1.2 times, 1.3 times, 1.4 times based on these.
  • the increase or decrease may be fold, 9 times, 10 times, 15 times, 20 times, 30 times, 40 times, 50 times, 100 times, or more.
  • the difference from the body fluid is 100%, 90%, 80%, 70%, 60 of the expression level of the reference body fluid.
  • % 50%, 40%, 30%, 20%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0 .8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, or less, or preferably 0%. ..
  • a method for early determination of the therapeutic effect of a neonatal perinatal disorder caused by fetal growth restriction in a mammalian subject is as described above for ⁇ -2-macroglobulin (A2m) (SEQ ID NO: 1), OX-2 membrane glycoprotein (Cd200) (SEQ ID NO: 2), polyubiquitin-.
  • A2m ⁇ -2-macroglobulin
  • Cd200 OX-2 membrane glycoprotein
  • polyubiquitin- polyubiquitin-.
  • Ubb (SEQ ID NO: 3), neurocerpin (Serpini1) (SEQ ID NO: 4), ubiquitin thioesterase OTUB1 (Otub1) (SEQ ID NO: 5), and ubiquitin-like modification activating enzyme 1 (Uba1) (SEQ ID NO: 6).
  • the proteins of at least one, preferably at least two, three, four or five, or all are used and the expression level of the protein is normal in body fluid samples obtained from the subject being treated. Tested in comparison to expression levels in normal body fluids, post-treatment body fluids, or body fluids known to exhibit perinatal disorders; and said expression levels as well as expression levels in said normal body fluids or post-treatment body fluids. The subject when it does not show a statistically significant difference in comparison or shows a statistically significant difference in comparison with the expression level in the body fluid known to show perinatal disorders. It can be determined that the treatment of perinatal disorders in Ubiquitin is effective.
  • Fluctuations in the expression level of the above proteins in body fluid samples include expression levels in normal body fluids, post-treatment body fluids (due to drugs, pluripotent stem cells, etc.), or body fluids known to exhibit perinatal disorders. It is done by comparison.
  • the reference body fluid is a normal body fluid or a body fluid after treatment
  • the difference from the standard body fluid is 100%, 90%, 80%, 70%, 60%, 50%, 40% of the expression level of the reference body fluid. , 30%, 20%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7 %, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, or less, or preferably 0%.
  • the expression level of the fluctuation is 1.1 times, 1.2 times, and 1. 3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 1.9 times, 2 times, 2.5 times, 3 times, 4 times, 5 times,
  • the increase or decrease may be 6 times, 7 times, 8 times, 9 times, 10 times, 15 times, 20 times, 30 times, 40 times, 50 times, 100 times, or more.
  • the present invention provides a method for early diagnosis of brain disorders (eg, neurodevelopmental disorders) in post-growth infants and children by capturing mild perinatal brain disorders that are difficult to detect with current diagnostic methods. Can be provided. According to the present invention, it is possible to diagnose a brain disorder that occurs after growth, which has been overlooked so far, in the neonatal period, and to capture a perinatal brain disorder that has not been diagnosed so far.
  • brain disorders eg, neurodevelopmental disorders
  • A2m ( ⁇ -2-macroglobulin)
  • BBB blood-brain barrier
  • Results Significant increases were confirmed in serum and cerebrospinal fluid both 5 days and 14 days after birth. In addition, suppression of expression by Muse cells was confirmed on both 5 days and 14 days after birth. In the results of cerebrospinal fluid, the inhibitory effect of Muse cells could not be confirmed at the stage of 5 days after birth, but what was confirmed in serum was A2 m due to fetal growth restriction even in organs other than the brain (lungs, etc.). It is considered that the upregulation of serum was induced and the Muse cells acted on the organ earlier than the brain.
  • Serpini1 neuroserpin
  • a type of serine protease inhibitor, neuroserpin is expressed in large amounts in the brain. In addition to suppressing proteolytic degradation by inhibiting proteolytic enzymes, it also controls inflammation. It is said that nerve cells are important for normal functioning and control memory and emotions. It has also been reported to have a neuroprotective effect. Dysfunction of this protein induces dementia. Results: Significant increases were confirmed in serum and cerebrospinal fluid both 5 days and 14 days after birth. As with cerebrospinal fluid, the degree of increase in serum samples is greater at 14 after birth. Furthermore, compared with cerebrospinal fluid, it was hardly confirmed in the control, so the rate of increase was large.
  • Cd200 OX-2 Membrane Glycoprotein
  • Ubb polyubiquitin-B Characteristic: A protein that functions as a label given when removing unnecessary proteins or abnormal proteins. Increased expression of this protein means an increase in unwanted proteins. In addition, abnormal expression fluctuations cause neurodegenerative diseases. Results: A significant increase was confirmed on both 5 and 14 days after birth. In addition, suppression of expression by Muse cells was confirmed on both 5 days and 14 days after birth. The effect is faster in Muse cells than in MSCs.
  • Uba1 (ubiquitin-like modification activating enzyme 1)
  • a type of ubiquitin activating enzyme which is a protein for activating ubiquitin for use in the next proteolysis of ubiquitin used for proteolysis. Like Ubb, it is an important molecule for protein quality control.
  • Uba1 may be referred to as "Ube1".
  • Otub1 ubiquitin thioesterase OTUB1
  • Deubiquitinating enzyme It is a protein for desorbing ubiquitin from ubiquitinated proteins and chromatin. Like Ubb, it is an important molecule for protein quality control.
  • ⁇ -2-macroglobulin SEQ ID NO: 1
  • OX-2 membrane glycoprotein Cd200
  • SEQ ID NO: 2 OX-2 membrane glycoprotein
  • Ubb polyubiquitin-B
  • Neurocerpin Serpini1
  • ubiquitin thioesterase OTUB1 Otub1
  • Uba1 ubiquitin-like modification activating enzyme 1
  • the proteomics profile contains information on at least two, at least three, at least four, at least five, or all expression levels of the above proteins in any combination.
  • the proteomics profile contains information on the level of expression of the protein, and one or more of the proteins tested statistically compared to the level of expression in normal or post-treatment body fluids.
  • the subject is diagnosed with perinatal disorder if it shows a significant difference or does not show a statistically significant difference compared to the expression level in the body fluid known to show perinatal disorder. do.
  • the "treatment" when the body fluid as a comparative reference is the body fluid after treatment is not limited, but is a treatment method for perinatal brain disorder (for example, hypothermia) as recognized by those skilled in the art.
  • therapies eg, umbilical cord blood stem cells, Muse cells.
  • “Muse (Multigeneage-Differentating Stress Enduring) cells” are bone marrow fluid, adipose tissue (Ogura, F., et al., Stem Cells Dev., Nov 20, 2013 (Epub) (published on Jan 17, 2014)) It can be obtained from skin tissues such as dermal connective tissue and is scattered in the connective tissues of each organ. In addition, these cells are cells having the properties of both pluripotent stem cells and mesenchymal stem cells. For example, the respective cell surface markers "SSEA-3 (Stage-specific embryonic antigen-3)" and " Identified as double positive for "CD105".
  • SSEA-3 Stage-specific embryonic antigen-3)
  • a Muse cell or a cell population containing a Muse cell can be separated from a living tissue using these antigen markers as an index, for example.
  • Muse cells are stress resistant and can be concentrated from mesenchymal tissues or cultured mesenchymal cells by various stress stimuli.
  • a cell fraction in which Muse cells are concentrated by stress stimulation can also be used. Details such as a method for separating Muse cells, a method for identifying them, and their characteristics are disclosed in International Publication No. WO2011 / 007900.
  • Wakao et al. 2011, supra, when mesenchymal cells are cultured from bone marrow, skin, etc.
  • SSEA-3 positive cells are CD105. It is known to be a positive cell. Therefore, when separating Muse cells from living mesenchymal tissues or cultured mesenchymal stem cells, Muse cells can be simply purified and used using SSEA-3 as an antigen marker. In the present specification, using SSEA-3 as an antigen marker, a cell population containing pluripotent stem cells (Muse cells) or Muse cells isolated from living mesenchymal tissues or cultured mesenchymal tissues is simply referred to as "Muse cells”. It may be described as "SSEA-3 positive cells”.
  • non-Muse cell refers to a stem cell contained in a living mesenchymal tissue or a cultured mesenchymal tissue, and is a stem cell other than the “SSEA-3 positive cell”.
  • a cell population obtained by removing SSEA-3 and CD105-positive cells from MSC can be used as non-Muse cells according to the method described in WO2011 / 007900 on Isolation and Identification of Human Muse Cells.
  • a Muse cell or a stem cell population containing Muse cells uses a living tissue (eg, an antibody against the cell surface marker SSEA-3 alone, or both antibodies against SSEA-3 and CD105, respectively).
  • a living tissue eg, an antibody against the cell surface marker SSEA-3 alone, or both antibodies against SSEA-3 and CD105, respectively.
  • Mesenchymal tissue refers to a living body of a mammal.
  • the living body does not include a fertilized egg or an embryo at a developmental stage before the blastogenic stage, but includes an embryo at a developmental stage after the blastogenic stage including a foetation or a blastoblast.
  • Mammals include, but are not limited to, primates such as humans and monkeys, rodents such as mice, rats and guinea pigs, rabbits, cats, dogs, sheep, pigs, cows, horses, donkeys, goats, ferrets and the like. Be done. Muse cells used in the cell preparations and pharmaceutical compositions of the present invention are clearly distinguished from embryonic stem cells (ES cells) and iPS cells in that they are separated directly from living tissues using markers.
  • ES cells embryonic stem cells
  • iPS cells embryonic stem cells
  • the "mesenchymal tissue” refers to tissues such as bone, synovium, fat, blood, bone marrow, skeletal muscle, dermis, ligaments, tendons, dental pulp, umbilical cord, and cord blood, and tissues existing in various organs.
  • Muse cells can be obtained from bone marrow, skin and adipose tissue. For example, it is preferable to collect mesenchymal tissue of a living body, separate Muse cells from this tissue, and use it. In addition, Muse cells may be separated from cultured mesenchymal cells such as fibroblasts and bone marrow mesenchymal stem cells by using the above-mentioned separation means. In the cell preparation and pharmaceutical composition of the present invention, the Muse cells used may be autologous or allogeneic to the recipient.
  • Muse cells or cell populations containing Muse cells can be separated from living tissues using, for example, SSEA-3 positive and double positive of SSEA-3 and CD105 as indicators, but human adult skin. Is known to include various types of stem cells and progenitor cells. However, Muse cells are not the same as these cells.
  • Such stem cells and progenitor cells include skin-derived progenitor cells (SKP), neural ridge stem cells (NCSC), melanoblasts (MB), perivascular cells (PC), endothelial progenitor cells (EP), and adipose-derived stem cells (ADSC). ).
  • SSEA-3 positive and double positive of SSEA-3 and CD105 as indicators, but human adult skin.
  • Such stem cells and progenitor cells include skin-derived progenitor cells (SKP), neural ridge stem cells (NCSC), melanoblasts (MB), perivascular cells (PC), endothelial progenitor cells (EP), and adipose-derived stem cells (ADSC).
  • Muse cells include CD34 (markers for EP and ADSC), CD117 (c-kit) (markers for MB), CD146 (markers for PC and ADSC), CD271 (NGFR) (markers for NCSC), NG2 (PC marker), vWF factor (Fonville brand factor) (EP marker), Sox10 (NCSC marker), Snai1 (SKP marker), Slug (SKP marker), Tyrp1 (MB marker), and At least one of 11 markers selected from the group consisting of Dct (MB marker), for example, 2, 3, 4, 5, 6, 7, 8, 9, 10 The non-expression of 11 or 11 markers can be separated as an index.
  • the non-expression of CD117 and CD146 can be used as an index
  • the non-expression of CD117, CD146, NG2, CD34, vWF and CD271 can be used as an index
  • the non-expression of 11 markers can be separated as an index.
  • Muse cells having the above characteristics are as follows: (I) Low or no telomerase activity; (Ii) Has the ability to differentiate into cells of any of the three germ layers; It may have at least one property selected from the group consisting of (iii) no neoplastic growth; and (iv) capable of self-renewal.
  • the Muse cells used in the cell preparations and pharmaceutical compositions of the present invention have all of the above properties.
  • "the telomerase activity is low or absent” means that, for example, when the telomerase activity is detected using TRAPEZE XL telomerase detection kit (Millipore), it is low or cannot be detected. say.
  • telomerase activity means, for example, telomerase having the same level of telomerase activity as somatic human fibroblasts, or 1/5 or less, preferably 1/10 or less of that of Hela cells. It means having activity.
  • Muse cells have the ability to differentiate into three germ layers (endoderm lineage, mesodermal lineage, and ectodermal lineage) in vitro and in vivo, and are, for example, induced and cultured in vitro. Can differentiate into hepatocytes, nerve cells, skeletal muscle cells, smooth muscle cells, bone cells, fat cells and the like. It may also show the ability to differentiate into three germ layers when transplanted into the testis in vivo.
  • Muse cells proliferate at a growth rate of about 1.3 days in suspension culture, but grow from one cell in suspension culture to form embryo-like cell clusters, and the growth slows down in about 14 days.
  • these embryo-like cell clusters are brought into the adhesive culture, cell proliferation is started again, and the cells proliferated from the cell cluster spread.
  • transplanted into the testis it has the property of not becoming cancerous for at least half a year.
  • Muse cells have a self-renewal (self-renewal) ability.
  • self-renewal means that the differentiation of cells contained in embryoid body-like cell clusters obtained by culturing one Muse cell in suspension culture into three germ layer cells can be confirmed, and at the same time, at the same time, it can be confirmed.
  • the next generation embryo-like cell mass is formed, and from there, the embryos in the three germ layer differentiation and suspension culture are again formed. It means that a skeletal cell mass can be confirmed.
  • Self-renewal may be repeated one or more cycles.
  • the cell fraction containing Muse cells gives an external stress stimulus to the mesenchymal tissue or cultured mesenchymal cells of the living body, kills cells other than the cells resistant to the external stress, and causes the surviving cells.
  • It may be a cell fraction enriched with SSEA-3 positive and CD105 positive pluripotent stem cells having at least one, preferably all of the following properties, obtained by a method involving recovery.
  • Iii Low or no telomerase activity;
  • Iv Has the ability to differentiate into three germ layers;
  • V) does not show neoplastic growth; and
  • (vi) has self-renewal ability.
  • the above external stresses are protease treatment, culture at low oxygen concentration, culture under low phosphoric acid condition, culture at low serum concentration, culture under low nutritional condition, culture under heat shock exposure, low temperature. Culturing in, freezing treatment, culturing in the presence of harmful substances, culturing in the presence of active oxygen, culturing under mechanical stimulation, culturing under shaking treatment, culturing under pressure treatment or physical impact It may be any or a combination of two or more.
  • the treatment time with the protease is preferably 0.5 to 36 hours in total in order to give external stress to the cells.
  • the protease concentration may be any concentration used when peeling the cells adhered to the culture vessel, breaking up the cell mass into a single cell, or recovering a single cell from the tissue.
  • the protease is preferably serine protease, aspartic protease, cysteine protease, metal protease, glutamate protease or N-terminal threonine protease. Further, it is preferable that the protease is trypsin, collagenase or dispase.
  • One pregnant rat in each group was bred at room temperature 22-24 ° C., humidity 50-60%, 12-hour light-dark cycle, and free access to food and water.
  • intrauterine hypoperfusion treatment was performed by attaching Ameloid Constrictors (Research Instruments SW, CA, US) to the uterine and ovarian arteries.
  • the uterus exposed when the Ameroid Constrictor was worn was wrapped in gauze soaked with saline warmed to 37 ° C to prevent dryness and decrease in body temperature.
  • the pregnant rats in the sham group only the laparotomy and uterine exposure treatment were performed on the 17th day of pregnancy as in the vehicle group, and the abdomen was closed without wearing the Ameloid Constrictor.
  • Example 2 Collection of cerebrospinal fluid A capillary (DRM Microcap, 1-000-0500) was purchased for collection of cerebrospinal fluid and sharpened by crushing the tip. The posterior fossa of the rat pups asleep with isoflurane was exposed, a sharpened capillary was punctured into the cisterna magna, and cerebrospinal fluid was collected by capillary action. The collected cerebrospinal fluid was placed in a tube to which a proteolytic enzyme inhibitor had been added in advance, immediately frozen in liquid nitrogen, and stored frozen at -80 ° C until use.
  • Example 3 Serum collection 500 ⁇ L of blood was collected from the heart of a rat pups asleep with isoflurane and placed in a microvascular (BD Microtainer SST) containing a coagulation promoter and a serum separator. After 5 inversion mixing, blood cell components were precipitated by centrifugation at 10000 ⁇ g, and serum was collected. A proteolytic enzyme inhibitor was added to the collected serum, and the serum was stored frozen at ⁇ 80 ° C. until use.
  • BD Microtainer SST microvascular
  • Example 4 Comprehensive analysis of proteins in cerebrospinal fluid by proteomics
  • the protein concentration in the collected cerebrospinal fluid was measured by the BCA method and unified to a concentration of 50 ⁇ g / 100 ⁇ L.
  • the abundance of total protein contained in cerebrospinal fluid was measured by a liquid chromatograph / mass spectrometer (LC / MS), and a protein profile was obtained.
  • the Spearman correlation coefficient between the abundance of all 601 proteins detected in the cerebrospinal fluid and the body weight on the third day of birth was calculated, and the p-value and false discovery rate (FDR) were calculated based on the correlation coefficient. ) was calculated. It has already been confirmed that the body weight on the third day of birth correlates with the body weight at birth.
  • the proteins showing p ⁇ 0.05 and FDR ⁇ 0.10 140 kinds on the 4th day of birth and 123 kinds on the 5th day, a total of 212 kinds (51 kinds of duplication) were confirmed, and these 212 kinds of proteins were confirmed. It was found as a protein that fluctuates with fetal growth restriction.
  • a group of proteins satisfying the conditions of p ⁇ 0.05, Fold Engineering> 2, and Symbols number> 3 was extracted by functional analysis of the 212 proteins using Gene Ontology.
  • proteins related to biological processes 333 proteins related to biological processes, 42 proteins related to cell components, 50 proteins related to molecular function, and 123 proteins on the 5th day of birth , 191 proteins related to biological processes, 27 proteins related to cell components, and 35 proteins related to molecular function were extracted.
  • the ones extracted at the top as showing particularly remarkable fluctuations are proteins related to the differentiation of neural stem cells and glial cells, neurogenesis and control of cell death on the 4th day of birth, and the 5th day.
  • protein groups responsible for inflammatory / immune response, cell adhesion, and protein structure management were commonly extracted on the 4th and 5th days of birth.
  • Example 5 Quantification of proteins by polyacrylamide gel electrophoresis and Western blotting Cerebral spinal fluid and serum proteins sample denaturing buffer (125 mM Tris-HCl [pH 6.8], 20% glycerol, 4% w / v sodium dodecyl sulfate [SDS] ], 0.001% w / v bromophenol blue and 10% mercaptoethanol), and the protein was denatured by heating at 95 ° C. for 5 minutes. For each sample, 5 ⁇ g of protein per lane was added to a 10% SDS-polyacrylamide gel and first electrophoresed at 80 V, 10 ° C. for 120 minutes.
  • SDS sodium dodecyl sulfate
  • the proteins separated by electrophoresis were transferred onto a polyvinylidene difluoride membrane (Merck Millipore, MA, USA) at room temperature and 400 mA for 1 hour. After blocking the protein on the membrane with 5% skim milk dissolved in Tris buffered physiological saline (pH 7.4) (TBS-T) containing 0.1% Tween-20, the primary antibody, rabbit anti-albumin antibody (Proteintech:). 16475-1-AP, 1: 5000), rabbit anti-A2m antibody (Abcam: ab58703, 1: 500), rabbit anti-Cd200 antibody (Proteintech: 14057-1-AP, 1: 200), rabbit anti-Ube1 (Uba1) antibody.
  • TSS-T Tris buffered physiological saline
  • the rat albumin molecule is 66 kDa
  • the A2m molecule is 163 kDa
  • the neuroselpin molecule is 46 kDa
  • the Ubb molecule is 34 kDa
  • the CD200 molecule is 41 kDa
  • the OTUB1 molecule is 31 kDa
  • the UBE1 molecule is. The appearance of the band was confirmed at 117 kDa.
  • the density of each detected band was quantified by background subtraction, and the quantified values of A2m, neuroserpin, Ubb, Cd200, OTUB1, and UBE1 were corrected by the quantified values of albumin of each sample (FIGS. 7A to 12A).
  • FIGS. 7B and C, 8B and C, FIG. 9B and C, FIGS. 10B and C, FIG. 11B, and FIG. 12B show the abundance of each protein in cerebrospinal fluid (births 5, 7, 10, and 14 days), while FIGS. 7C, 8C, 9C, and 10C indicates the abundance of each protein in serum (5th and 14th day of birth).
  • A2m ( ⁇ -2-macroglobulin)
  • suppression of expression by Muse cells was confirmed on both 5 days and 14 days after birth (FIGS. 7B and C).
  • the inhibitory effect of Muse cells could not be confirmed at the stage of 5 days after birth (Fig. 7B), but what was confirmed in serum was the fetus in organs other than the brain (lungs, etc.). It is considered that the growth restriction induces the upregulation of A2m, and the Muse cells act on the organ earlier than the brain.
  • E Otub1 (ubiquitin thioesterase OTUB1)
  • Muse cells In cerebrospinal fluid, the expression of Muse cells was confirmed to be suppressed by Muse cells and MSCs on both 5 days and 14 days after birth. The effect is faster in Muse cells than in MSCs (Fig. 11B).
  • Uba1 ubiquitin-like modification activating enzyme 1
  • Muse cells In cerebrospinal fluid, the expression of Muse cells was confirmed to be suppressed by Muse cells and MSCs on both 5 days and 14 days after birth. The effect is faster in Muse cells than in MSCs (Fig. 12B).
  • PBS phosphate buffered saline
  • PFA paraformaldehyde
  • Brain samples were post-fixed with 4% PFA dissolved in 0.1 M phosphate buffer for 24 hours and then phosphate buffered sucrose containing 0.1% sodium azide (10% sucrose, 4-6 hours, 20% sucrose, 4-6 hours, 30% sucrose, 12-36 hours) was cryoprotected and rapidly frozen at ⁇ 80 ° C. After freezing, brain sections were sliced in the coronal direction to a thickness of 40 ⁇ m. The prepared section was blocked with 10% normal goat serum for 1 hour at room temperature, and then the primary antibody rabbit anti-A2m antibody (Abcam: ab58703, 1:50) and rabbit anti-CD200 antibody (Proteintech: 14057-1-AP, 1:50).
  • rabbit anti-Ube1 (Uba1) antibody (Proteintech: 15912-1-AP, 1:50), or rabbit anti-neuroseperpine antibody Abcam: ab33077, 1: 100) was reacted at 4 ° C. for 20 hours. After washing 3 times with PBS for 5 minutes, ATTO 488 conjugated secondary antibody goat anti-rabbit IgG (Rockland, 611-152-122, 1: 500) was reacted at 4 ° C. for 12 hours.
  • Mouse anti-S100 antibody (Abcam: ab4066, 1: 100) or mouse anti-Iba1 antibody (Abcam: ab15690, 1: 100) was reacted at 4 ° C. for 20 hours. Each of these antibodies was used as a marker for nerve cells, oligodendrocytes, astrocytes, and microglia.
  • ATTO 550 conjugated secondary antibody goat anti-mouse IgG (Rockland, 611-152-122, 1: 500) was reacted at 4 ° C. for 12 hours. After washing with PBS 3 times for 5 minutes, the cells were passed through purified water once and encapsulated with nuclear staining using Prolong Gold with DAPI. After drying, the observation was performed using a confocal laser scanning microscope (TiE-A1R, Nikon, Japan). Select 10 sections nasally from the intersection of the sagittal and coronal sutures (Bregma) of the brain, and observe the hippocampus (Fig. 13A), striatum (Fig. 14A), and cerebral cortex (Fig. 15A) of each section.
  • 100 cells were randomly selected from each brain region, and the expression levels of the four biomarker candidate proteins in NeuN-positive cells, Olig2-positive cells, S100-positive cells, and Iba1-positive cells were relative to the fluorescence intensity. Quantified. Of the 100 cells, the one in which the four candidate proteins showed the highest intensity was set to 100, and the non-expressing cell was set to 0.
  • CD200 showed strong expression in S100-positive cells in both the sham-surgery group and the FGR group, followed by NeuN-positive cells. In these cells, CD200 was more strongly expressed in the FGR group than in the sham surgery group. Ubb was detected in NeuN-positive cells, S100-positive cells and Olig2-positive cells, and its expression intensity was significantly increased in the FGR group. In addition, these results were very similar in all brain regions of the cerebral cortex, hippocampus, and striatum. From these results, it was clarified that the four biomarker candidate proteins were significantly upregulated in the brain tissue. It was also shown that the expression variation of the candidate protein depends not on the brain region but on the type of brain cells.
  • the biomarker of the present invention can be used for early diagnosis of perinatal disorders in newborns due to fetal growth restriction in mammalian subjects, and is applied to the treatment of neurodevelopmental disorders in infants and children. be able to.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Le but de la présente invention est de fournir une méthode d'évaluation et de diagnostic permettant de prédire les troubles du développement neurologique à un stade précoce, de déterminer la politique de traitement optimale et d'évaluer l'effet du traitement d'intervention chez les nouveau-nés à un stade précoce, en diagnostiquant de manière appropriée et précise, avec une précision élevée, les troubles cérébraux périnataux (par exemple, les troubles du développement neurologique) chez les nouveau-nés associés à une restriction de croissance fœtale. Selon la présente invention, il est fourni une méthode pour déterminer, à un stade précoce, les troubles cérébraux périnataux des nouveau-nés causés par une restriction de croissance fœtale, la méthode faisant intervenir (a) un processus d'évaluation des niveaux d'expression d'une ou plusieurs protéines choisies dans le groupe constitué par l'α-2-macroglobuline (A2m), la glycoprotéine membranaire OX-2 (Cd200), la polyubiquitine-B (Ubb), la neuroséropine (Serpini1), l'ubiquitine thioestérase OTUB1 (Otub1) et l'enzyme activatrice du modificateur de type ubiquitine 1 (Uba1) dans un échantillon de fluide corporel obtenu auprès d'un sujet, en comparaison avec les niveaux d'expression dans un fluide corporel témoin.
PCT/JP2021/006475 2020-02-21 2021-02-19 Indice d'évaluation quantitative pour restriction de croissance foetale Ceased WO2021167098A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022501095A JPWO2021167098A1 (fr) 2020-02-21 2021-02-19

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020028828 2020-02-21
JP2020-028828 2020-02-21

Publications (1)

Publication Number Publication Date
WO2021167098A1 true WO2021167098A1 (fr) 2021-08-26

Family

ID=77390905

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/006475 Ceased WO2021167098A1 (fr) 2020-02-21 2021-02-19 Indice d'évaluation quantitative pour restriction de croissance foetale

Country Status (2)

Country Link
JP (1) JPWO2021167098A1 (fr)
WO (1) WO2021167098A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116179681A (zh) * 2022-12-26 2023-05-30 朗肽生物制药股份有限公司 环状rnazbtb10及其检测引物和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130295679A1 (en) * 2010-11-16 2013-11-07 University College Cork - National University Of Ireland, Cork Prediction of a small-for-gestational age (sga) infant
JP2015533504A (ja) * 2012-10-19 2015-11-26 ウェイン ステイト ユニヴァーシティ 出生前診断のための頚管粘液における胎性栄養膜細胞の同定および分析
JP2017516119A (ja) * 2014-05-16 2017-06-15 セザンヌ ソシエテ パ アクシオンス シンプリフィエ 初期胎盤インスリン様ペプチド（プロ（ｐｒｏ）−ＥＰＩＬ）
WO2018235878A1 (fr) * 2017-06-20 2018-12-27 国立大学法人名古屋大学 Amélioration et traitement d'un trouble cérébral résultant d'un retard de croissance de fœtus à l'aide de cellules souches pluripotentes
JP2020502533A (ja) * 2016-12-23 2020-01-23 パングラッツ−フューラー，スザンネ 新生児脳損傷の診断におけるアルファ−ｂクリスタリン

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130295679A1 (en) * 2010-11-16 2013-11-07 University College Cork - National University Of Ireland, Cork Prediction of a small-for-gestational age (sga) infant
JP2015533504A (ja) * 2012-10-19 2015-11-26 ウェイン ステイト ユニヴァーシティ 出生前診断のための頚管粘液における胎性栄養膜細胞の同定および分析
JP2017516119A (ja) * 2014-05-16 2017-06-15 セザンヌ ソシエテ パ アクシオンス シンプリフィエ 初期胎盤インスリン様ペプチド（プロ（ｐｒｏ）−ＥＰＩＬ）
JP2020502533A (ja) * 2016-12-23 2020-01-23 パングラッツ−フューラー，スザンネ 新生児脳損傷の診断におけるアルファ−ｂクリスタリン
WO2018235878A1 (fr) * 2017-06-20 2018-12-27 国立大学法人名古屋大学 Amélioration et traitement d'un trouble cérébral résultant d'un retard de croissance de fœtus à l'aide de cellules souches pluripotentes

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
CHEN RONG-JUN ET AL.: "Effects of intrauterine growth restriction on gene expression in small intestine of piglets", ANIMAL HUSBANDRY AND FEED SCIENCE, vol. 1, no. 4-5, 2009, pages 41 - 46 *
DESSÌ ANGELICA, MURGIA ANTONIO, AGOSTINO ROCCO, PATTUMELLI MARIA, SCHIRRU ANDREA, SCANO PAOLA, FANOS VASSILIOS, CABONI PIERLUIGI: "Exploring the Role of Different Neonatal Nutrition Regimens during the First Week of Life by Urinary GC-MS Metabolomics", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 17, no. 2, 22 February 2016 (2016-02-22), XP055856109, DOI: 10.3390/ijms17020265 *
GACCIOLI FRANCESCA; AYE IRVING L.M.H.; SOVIO ULLA; CHARNOCK-JONES D. STEPHEN; SMITH GORDON C.S.: "Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers", AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY, MOSBY, ST LOUIS, MO, US, vol. 218, no. 2, 22 December 2017 (2017-12-22), US , XP086376106, ISSN: 0002-9378, DOI: 10.1016/j.ajog.2017.12.002 *
HASHIMOTO, MAKOTO ET AL.: "Relationship between short term growth and insulin-like growth factor at three weeks and five weeks old in premature infant", JOURNAL OF JAPAN SOCIETY FOR NEONATAL HEALTH AND DEVELOPMENT, vol. 31, no. 1, 15 February 2019 (2019-02-15), pages 83 - 89 *
HAYYAKAWA, MASAHIRO ET AL.: "Research on histological and molecular biological changes in central nerves of rat in intrauterine fetal growth restriction model", JOURNAL OF JAPAN SOCIETY OF PERINATAL AND NEONATAL MEDICINE, vol. 44, December 2008 (2008-12-01), pages 20 *
HUANG SHIMENG; LI NA; LIU CONG; LI TIANTIAN; WANG WEI; JIANG LILI; LI ZHEN; HAN DANDAN; TAO SHIYU; WANG JUNJUN: "Characteristics of the gut microbiota colonization, inflammatory profile, and plasma metabolome in intrauterine growth restricted piglets during the first 12 hours after birth", THE JOURNAL OF MICROBIOLOGY, THE MICROBIOLOGICAL SOCIETY OF KOREA // HAN-GUG MISAENGMUL HAG-HOE, KR, vol. 57, no. 9, 11 June 2019 (2019-06-11), KR , pages 748 - 758, XP036872817, ISSN: 1225-8873, DOI: 10.1007/s12275-019-8690-x *
KARAMESSINIS PANAGIOTIS M., ARIADNE MALAMITSI-PUCHNER, THEODORA BOUTSIKOU, MANOUSOS MAKRIDAKIS, KONSTANTINOS VOUGAS, MICHAEL FOUNT: "Marked defects in the expression and glycosylation of alpha2-HS glycoprotein/fetuin-A in plasma from neonates with intrauterine growth restriction: proteomics screening and potential clinical implications", MOLECULAR & CELLULAR PROTEOMICS : MCP, vol. 7, no. 3, 7 December 2007 (2007-12-07), pages 591 - 599, XP055856114, DOI: 10.1074/mcp.M700422-MCP200 *
KINJO, TADAMUNE ET AL.: "Research on etiology and pathology of fetal growth restriction (FGR) understood from abnormality in innate immune system - about relationship between vasculitis and human FGR development", ANNUAL REPORT OF FUKUOKA CHILDREN'S HOSPITAL, vol. 38, December 2017 (2017-12-01), pages 209 - 210 *
ONODA, ATSUTO ET AL.: "Analysis of proteome in cerebrospinal fluid in perinatal brain damage caused by fetal growth restriction", PHARMACEUTICAL HEALTH SCIENCE ENVIRONMENTAL TOXICOLOGY, vol. 2019, 17 August 2019 (2019-08-17), pages 151 *
ONODA, ATSUTO ET AL.: "Comprehensive analysis of protein in cerebrospinal fluid of rat in fetal growth retardation model", THE 55TH JOURNAL OF JAPAN SOCIETY OF PERINATAL AND NEONATAL MEDICINE, 2019, pages 313 *
RUIS-GONZALEZ MARIA D., MARIA D. CANETE, JOSÉ L. GOMEZ-CHAPARRO, NIEVES ABRIL, RAMON CANETE, JUAN LOPEZ-BAREA: "Alterations of protein expression in serum of infants with intrauterine growth restriction and different gestational ages", JOURNAL OF PROTEOMICS, vol. 119, 24 April 2015 (2015-04-24), pages 169 - 182, XP055856116, DOI: 10.1016/j.jprot.2015.02.003 *
SHARP ANDREW; JACKSON RICHARD; CORNFORTH CHRISTINE; HARROLD JANE; TURNER MARK A.; KENNY LOUISE; BAKER PHILIP N.; JOHNSTONE EDWARD : "A prediction model for short-term neonatal outcomes in severe early-onset fetal growth restriction", EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, ELSEVIER IRELAND LTD., IE, vol. 241, 16 August 2019 (2019-08-16), IE , pages 109 - 118, XP085833816, ISSN: 0301-2115, DOI: 10.1016/j.ejogrb.2019.08.007 *
SHOUJI, HIROMICHI ET AL.: "Review of analysis of urinary metabolome of intrauterine growth restricted mice", THE JOURNAL OF THE JAPAN PEDIATRIC SOCIETY, vol. 120, no. 2, 1 February 2016 (2016-02-01), pages 238 *
STRINI} TOMISLAV, BUKOVI} DAMIR, RADI} ANTE, UMILIN LADA [, HAUPTMAN DINKO, SOVI} TOMISLAV: "Comparison of Fetal Plasma Cortisol Level between Eutrophic and Hypotrophic Newborns", COLLEGIUM ANTROPOLOGICUM, vol. 29, no. 2, 1 January 2005 (2005-01-01), pages 739 - 741, XP055856111 *
TSUGE MITSURU; HIDA AKIRA I.; MINEMATSU TOSHIO; HONDA NAOTOSHI; OSHIRO YUMI; YOKOYAMA MIKIFUMI; KONDO YOICHI: "Prospective Cohort Study of Congenital Cytomegalovirus Infection during Pregnancy with Fetal Growth Restriction: Serologic Analysis and Placental Pathology", JOURNAL OF PEDIATRICS., MOSBY-YEAR BOOK, ST. LOUIS, MO, US, vol. 206, 6 November 2018 (2018-11-06), US , pages 42, XP085610843, ISSN: 0022-3476, DOI: 10.1016/j.jpeds.2018.10.003 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116179681A (zh) * 2022-12-26 2023-05-30 朗肽生物制药股份有限公司 环状rnazbtb10及其检测引物和用途
CN116179681B (zh) * 2022-12-26 2023-09-22 朗肽生物制药股份有限公司 环状rnazbtb10及其检测引物和用途

Also Published As

Publication number Publication date
JPWO2021167098A1 (fr) 2021-08-26

Similar Documents

Publication Publication Date Title
JP5011410B2 (ja) 生体液のプロテオーム分析
Rajan et al. Defining molecular identity and fates of CNS-border associated macrophages after ischemic stroke in rodents and humans
KR101406393B1 (ko) 신경교세포 생성 조절에 관여하는 fam19a5의 약제학적 용도
JP2006524331A5 (fr)
JP5976732B2 (ja) 神経学的状態のバイオマーカー検出方法およびアッセイ
AU2010291933B2 (en) Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
JP6707181B2 (ja) 早産のリスクがある妊娠女性を同定するためのキットまたはパッケージ、および、当該キットまたはパッケージの使用
Lu et al. CXCR4, CXCR7, and CXCL12 are associated with trophoblastic cells apoptosis and linked to pathophysiology of severe preeclampsia
JP2010509596A (ja) 妊娠中の雌における子宮内感染の検出または早産のリスクの決定のための子宮頸部液のプロテオーム解析
Yan et al. Glycolysis inhibition ameliorates brain injury after ischemic stroke by promoting the function of myeloid-derived suppressor cells
Bhatti et al. The amniotic fluid proteome changes with gestational age in normal pregnancy: a cross-sectional study
Zhang et al. HMGB1 translocation after ischemia in the ovine fetal brain
KR102446567B1 (ko) 각막 내피 세포의 기능 부전 진단용 바이오마커
WO2021167098A1 (fr) Indice d'évaluation quantitative pour restriction de croissance foetale
TW202136297A (zh) Tau蛋白病變及失智症相關疾病之判定藥及判定方法
CN116953247A (zh) 一种用于早期诊断阿尔茨海默症的生物标志物及其用途
Kumar et al. Dynamic alteration in the vaginal secretory proteome across the early and mid-trimesters of pregnancy
WO2023201511A1 (fr) Biomarqueur pour le diagnostic précoce de la maladie d'alzheimer et son utilisation
Castagna et al. Female urinary proteomics: New insight into exogenous and physiological hormone‐dependent changes
CN110777201B (zh) 骨桥蛋白在缺氧缺血性脑损伤中的应用
RU2480762C1 (ru) Способ прогноза формирования эссенциальной артериальной гипертензии у женщин с гипертензивными нарушениями при беременности
RU2233121C1 (ru) Способ прогнозирования течения беременности и определения степени риска нарушений развития эмбриона/плода и рождения ребенка с различными отклонениями
Zhang et al. Separate and synergistic effect of progesterone and estradiol on induction of annexin 2 and its interaction protein p11 in pregnant sheep myometrium
RU2414715C1 (ru) Способ прогнозирования церебральных поражений у новорожденных
Verma Discovery and Targeted Validation of Early Pregnancy Biomarkers in Cattle Urine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21757861

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022501095

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21757861

Country of ref document: EP

Kind code of ref document: A1